Tsinghua University

Jya-Wei Cheng

Hui-Yuan Yu

Hsi-Tsung Cheng

Kuo-Chun Huang

Hung-Lun Chu

Cheng-Yu Tsai

Lee-Wei Yang

Hong-Chun Li

Ya-Han Chih

The present invention provides an evaluating system and the use thereof for the efficacy of antimicrobial peptide, which includes the following steps: (a) constructing a peptide by a first input unit, and load the peptide into an aqueous solution for a first time for equilibration; (b) constructing a lipid bilayer by a second input unit, and load the lipid bilayer into an aqueous solution for a second time for equilibration; (c) Using a first processing unit, simulations are carried out for an aqueous system containing an equilibrated peptide from the first input unit and the equilibrated lipid bilayer from the second input unit; (d) calculating the partition free energy of the peptide by a second processing unit; (e) outputting the prediction by an output unit, wherein the output unit is connected with the first processing unit and the second processing unit.

In silico design of peptides equilibrated in a lipid bilayer with partition free energies indicating probability of antimicrobial activity

An anti-endotoxin polypeptide is provided. The anti-endotoxin polypeptide having the formula (I) A-L-C, wherein Aand Cindependently is a short peptide with &#x3b1;-helix, L is AGP (Ala-Gly-Pro) or a peptide bond, and the hydrophobicity of the hydrophobic terminus in the anti-endotoxin polypeptide is between about 0.425 and 0.765. The anti-endotoxin polypeptide of the invention can neutralize the lipopolysaccharide and has the low hemolysis and high salt resistance, simultaneously. The present invention also provides a method for design an anti-endotoxin polypeptide, the anti-endotoxic activity is adjusted through increasing and/or decreasing hydrophobicity of the hydrophobic terminal end.

Anti-endotoxin polypeptide

A peptide with antimicrobial, anticancer and/or wound-healing promoting activities is provided. The peptide with antimicrobial, anticancer and/or wound-healing promoting activities, includes: an &#x3b1;-helix peptide; and a short peptide consisting of about 4-10 positively charged amino acids, connected to an N-terminus of the &#x3b1;-helix peptide to form the peptide with antimicrobial, anticancer and/or wound-healing promoting activities, wherein the total length of the peptide with antimicrobial, anticancer and/or wound-healing promoting activities is about 10-20 amino acids.

Peptides with antimicrobial, anticancer and/or wound-healing promoting activities, pharmaceutical compositions containing the same, and use of the peptides with antimicrobial, anticancer and/or wound-healing promoting activities

An antimicrobial peptide has an amino terminal and/or carboxyl terminal linked with at least one artificial bulky amino acid to increase the salt resistance and protease resistance of the antimicrobial peptide. The antimicrobial peptide of the invention has a high salt resistance, a high protease resistance, and a low hemolytic activity, simultaneously.

Salt and protease-resistance of antimicrobial peptide and the manufacture thereof

The present invention is related to a high salt-resistance antibacterial peptide by increasing width of side chain of amino acids and/or increasing length of side chain of amino acids in the antibacterial peptide; and a method for increasing salt-resistance of antibacterial peptide by increasing width of side chain and/or increasing length of side chain in the antibacterial peptide.

High salt-resistance antibacterial peptide and method for producing the same

Enclosed is an antagonist, which includes a peptide chain represented by an amino acid sequence. The amino acid sequence has a short sequence, C-X1X2X3X4X5-N, which is situated before and neighbored to the third cysteine (Cys, C) of the N-terminus, wherein X1 is an amino acid with aromatic ring, hydrophobic property or long chain, and X2, X3, X4 and X5 are glutamine (G), serine (S), alanine (A) and proline (P) respectively. In one embodiment, X1 is phenylalanine (F). The present antagonists can be used to inhibit or treat with the diseases caused by the activated cells expressing CXCR1 and/or CXCR2 receptor, for example, the acute or chronic inflammatory reaction induced with polymorphonuclear neutrophils (PMNs) expressing CXCR1 and/or CXCR2 receptor, and angiogenesis accompanied by tumor growth inhibition.

Growing community of inventors

Hsinchu, Taiwan

Jya-Wei Cheng